Related Experiment Videos
Cationic amphiphilic drug-induced phospholipidosis
1Schering-Plough Research Institute, Lafayette, New Jersey 07848, USA.
Toxicologic Pathology
|January 1, 1997
Summary
Phospholipidosis is a disorder of excessive phospholipid accumulation, often induced by cationic amphiphilic drugs (CADs). Each drug
Area of Science:
- Pharmacology
- Cell Biology
- Toxicology
Background:
- Phospholipidosis involves excessive intracellular phospholipid accumulation.
- Phospholipids are vital for cell membranes and cytoskeleton.
- Drug-induced phospholipidosis can occur due to agents interacting with phospholipid metabolism.
Purpose of the Study:
- To review phospholipid metabolism and the characteristics of cationic amphiphilic drugs (CADs).
- To discuss the induction, effects, and risk assessment of drug-induced phospholipidosis.
- To explore the mechanism of phospholipidosis, particularly in the lung.
Main Methods:
- Review of literature on phospholipid metabolism and drug interactions.
- Analysis of physiochemical properties of cationic amphiphilic drugs (CADs).
- Examination of animal and human data on phospholipidosis specificity and effects.
Main Results:
- Cationic amphiphilic drugs (CADs) share specific physiochemical properties.
- Phospholipidosis induction varies between animal models and humans.
- Drug interactions and active metabolites influence phospholipidosis development.
Conclusions:
- Each drug inducing phospholipidosis requires separate risk assessment in humans.
- Factors like therapeutic class and organ selectivity are crucial for risk evaluation.
- Generalizations about drug-induced phospholipidosis are not advisable; individual evaluation is necessary.